Calidi Biotherapeutics Inc (CLDI)

$0.22 -0.01 (-2.31%)
Market Cap 7.28M
Revenue (ttm) 0.00
Net Income (ttm) -22.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 636,300
Avg Vol 857,352
Day's Range N/A - N/A
Shares Out 31.79M
Stochastic %K 15%
Beta 1.07
Analysts Strong Sell
Price Target $10.00

Company Profile

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcino...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 9600
Fax: 858 794 9605
Address:
4475 Executive Drive, Suite 200, San Diego, United States
NetworkNewsWire
NetworkNewsWire Jun. 27 at 7:06 PM
BioMedNewsBreaks – $CLDI Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter https://ibn.fm/ljXqg
0 · Reply
VinWeezel
VinWeezel Jun. 27 at 1:20 PM
$CLDI https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-announces-shareholder-letter-from-795elcc4qint.html
0 · Reply
Ophirbenben5
Ophirbenben5 Jun. 27 at 11:06 AM
$CLDI when is the meeting?
1 · Reply
dwadmi
dwadmi Jun. 27 at 10:32 AM
$CLDI huge movement soon
1 · Reply
ROARINGLIONN
ROARINGLIONN Jun. 26 at 10:10 PM
$CLDI yes 👍
0 · Reply
ROARINGLIONN
ROARINGLIONN Jun. 26 at 10:05 PM
$CLDI fDA clearance let FULLKKKIN GOOOOOOO
0 · Reply
tntz_79
tntz_79 Jun. 26 at 7:25 PM
$CLDI when is bankruptcy? Asking for a friend
0 · Reply
uindicator
uindicator Jun. 26 at 2:20 PM
$CLDI what a dud, new CEO doing fuck all
1 · Reply
Bucky712
Bucky712 Jun. 26 at 11:24 AM
$CLDI it’s time
0 · Reply
E8000
E8000 Jun. 25 at 6:56 PM
$CLDI it’s over
1 · Reply
Latest News on CLDI
Calidi Biotherapeutics Announces Shareholder Letter from CEO

Jun 27, 2025, 8:00 AM EDT - 14 hours ago

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Innovation In Indexing: Why Passive ETFs Matter

May 22, 2025, 7:43 AM EDT - 5 weeks ago

Innovation In Indexing: Why Passive ETFs Matter

ELFY INVN OWNB PEVC SPY TOV XIDV

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Apr 25, 2025, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

Apr 16, 2025, 9:30 AM EDT - 2 months ago

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 31, 2025, 4:30 PM EDT - 3 months ago

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 28, 2025, 9:00 AM EDT - 3 months ago

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Mar 10, 2025, 8:00 AM EDT - 3 months ago

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 28, 2025, 9:00 AM EST - 4 months ago

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Feb 24, 2025, 8:00 AM EST - 4 months ago

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

Jan 29, 2025, 8:00 AM EST - 5 months ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Jan 28, 2025, 8:00 AM EST - 5 months ago

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Jan 10, 2025, 4:30 PM EST - 6 months ago

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Jan 10, 2025, 8:30 AM EST - 6 months ago

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Proposed Public Offering

Jan 8, 2025, 4:01 PM EST - 6 months ago

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Nov 15, 2024, 4:05 PM EST - 8 months ago

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Nov 14, 2024, 8:30 AM EST - 8 months ago

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Nov 12, 2024, 5:29 PM EST - 8 months ago

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 25, 2024, 9:00 AM EDT - 8 months ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Oct 24, 2024, 8:30 AM EDT - 8 months ago

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Oct 23, 2024, 8:31 AM EDT - 8 months ago

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Oct 18, 2024, 11:00 PM EDT - 8 months ago

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 18, 2024, 8:45 AM EDT - 9 months ago

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GRRR

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 13, 2024, 5:37 PM EDT - 11 months ago

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 2, 2024, 9:00 AM EDT - 11 months ago

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

Jul 29, 2024, 9:00 AM EDT - 11 months ago

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi to Effect Reverse Stock Split

Jul 5, 2024, 4:15 PM EDT - 1 year ago

Calidi to Effect Reverse Stock Split

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Jun 11, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

May 31, 2024, 8:51 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

May 17, 2024, 9:00 AM EDT - 1 year ago

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

UMAC

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

May 14, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

May 1, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Apr 19, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Apr 16, 2024, 8:31 AM EDT - 1 year ago

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Mar 15, 2024, 4:05 PM EDT - 1 year ago

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Feb 12, 2024, 7:00 AM EST - 1 year ago

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Jan 8, 2024, 7:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Dec 13, 2023, 7:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 14, 2023, 4:05 PM EST - 1 year ago

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)

Nov 3, 2023, 7:00 AM EDT - 1 year ago

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Sep 13, 2023, 5:50 AM EDT - 1 year ago

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

NetworkNewsWire
NetworkNewsWire Jun. 27 at 7:06 PM
BioMedNewsBreaks – $CLDI Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter https://ibn.fm/ljXqg
0 · Reply
VinWeezel
VinWeezel Jun. 27 at 1:20 PM
$CLDI https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-announces-shareholder-letter-from-795elcc4qint.html
0 · Reply
Ophirbenben5
Ophirbenben5 Jun. 27 at 11:06 AM
$CLDI when is the meeting?
1 · Reply
dwadmi
dwadmi Jun. 27 at 10:32 AM
$CLDI huge movement soon
1 · Reply
ROARINGLIONN
ROARINGLIONN Jun. 26 at 10:10 PM
$CLDI yes 👍
0 · Reply
ROARINGLIONN
ROARINGLIONN Jun. 26 at 10:05 PM
$CLDI fDA clearance let FULLKKKIN GOOOOOOO
0 · Reply
tntz_79
tntz_79 Jun. 26 at 7:25 PM
$CLDI when is bankruptcy? Asking for a friend
0 · Reply
uindicator
uindicator Jun. 26 at 2:20 PM
$CLDI what a dud, new CEO doing fuck all
1 · Reply
Bucky712
Bucky712 Jun. 26 at 11:24 AM
$CLDI it’s time
0 · Reply
E8000
E8000 Jun. 25 at 6:56 PM
$CLDI it’s over
1 · Reply
E8000
E8000 Jun. 25 at 1:51 PM
$CLDI RS for sure
0 · Reply
E8000
E8000 Jun. 25 at 1:49 PM
$CLDI this stock is a It's a dog with fleas
0 · Reply
Pennystockguru1
Pennystockguru1 Jun. 25 at 1:06 PM
$CLDI less than a week is the annual meeting. A stock split is being voted on and should pass. That is good for the stock at this point. Typically companies also try to announce any other positive news around events like those. For those waiting for news, it will likely happen soon.
4 · Reply
dwadmi
dwadmi Jun. 25 at 8:26 AM
$CLDI
0 · Reply
NetworkNewsWire
NetworkNewsWire Jun. 24 at 6:59 PM
Could Wheat Germ Hold the Key to Supercharging Immunotherapy? New Research Hopes to Find Out $CLDI https://ibn.fm/GVIpJ #biomedstocks #Immunotherapy
0 · Reply
Pennystockguru1
Pennystockguru1 Jun. 24 at 5:44 PM
$CLDI for anyone posting about an imminent BK or this is dead money, I think the post from the company yesterday about the CEO attending an industry conference last week and meeting with lots of companies would be quite odd timing wise if so. I think once all the momentum manipulation that started after hours yesterday goes away, that this will steady. With any good news it could really potentially pop with a short squeeze including many of those same play. Not financial advice.
1 · Reply
uindicator
uindicator Jun. 24 at 4:32 PM
$CLDI no point in putting more money into this, looks like they’re running out of cash , my money looking like zero . New CEO was supposed to be raising money , might end up like his last company
1 · Reply
Ophirbenben5
Ophirbenben5 Jun. 24 at 3:57 PM
$CLDI big manipulation will finish soon….
1 · Reply
Ophirbenben5
Ophirbenben5 Jun. 24 at 3:57 PM
$CLDI were keeping down with volume.. I don’t like it
0 · Reply
sepsis74
sepsis74 Jun. 24 at 2:31 PM
$CLDI the company raised money at $0.85 in January and $1.69 in November 2024. There haven't been any research failures since then. It's a money problem. With a market cap of less than $8M and debt of $4.7M, you'd hope someone would just buy the company for its I.P. Armistice has 10.6% of this company, worth a measly $800K now. Why not just buy the whole company.
1 · Reply
sepsis74
sepsis74 Jun. 24 at 2:12 PM
$CLDI Ladenburg Thalham, serving up trash since forever.
0 · Reply
BHH1385
BHH1385 Jun. 24 at 1:44 PM
$CLDI bankruptcy looms….
4 · Reply